First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors - Concepedia

Concepedia

Publication | Open Access

First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors

DOI Full Paper Access

341

Citations

10

References

2015

Year

Alexander Starodub, Allyson J. Ocean, Manish A. Shah, Michael J. Guarino, Vincent J. Picozzi, Linda T. Vahdat, Sajeve Thomas, Serengulam V. Govindan, Pius Maliakal, William A. Wegener,

Clinical Cancer Research

Abstract

Sacituzumab govitecan had acceptable toxicity and encouraging therapeutic activity in patients with difficult-to-treat cancers. The 8 and 10 mg/kg doses were selected for phase II studies.

References

	Year	Citations

Page 1